Faeth Therapeutics (STU:4070) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:4070 Faeth Therapeutics Inc STU:4070
21 GF Score
Price €5.60
! 2 Warning Signs
View Full Analysis

What is Faeth Therapeutics FFO?

FFO (Funds from operations) only applies to REITs.

STU:4070
21GF Score
Faeth Therapeutics Inc STU:4070
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Faeth Therapeutics Business Description

Other Exchanges FTH:USA
Address 701 Tillery Street No. 12, No.1010, Austin, TX, USA, 78702
Faeth Therapeutics Inc is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The company's principal program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer.
21GF Score

Get the complete analysis for STU:4070

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.60
Price